A Randomized, Double-Blind, Multi-Center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Gastric cancer
Focus Registrational; Therapeutic Use
Acronyms GRANITE-1
Sponsors Novartis Pharmaceuticals

Most Recent Events

05 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
19 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
16 Sep 2013 Results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight